Literature DB >> 26271953

Cannabis in the Treatment of Dystonia, Dyskinesias, and Tics.

Barbara S Koppel1.   

Abstract

Cannabis has been used for many medicinal purposes, including management of spasms, dystonia, and dyskinesias, with variable success. Its use for tetanus was described in the second century BCE, but the literature continues to include more case reports and surveys of its beneficial effects in managing symptoms of hyperkinetic movement disorders than randomized controlled trials, making evidence-based recommendations difficult. This paper reviews clinical research using various formulations of cannabis (botanical products, oral preparations containing ∆(9)-tetrahydrocannabinol and/or cannabidiol) and currently available preparations in the USA (nabilone and dronabinol). This has been expanded from a recent systematic review of cannabis use in several neurologic conditions to include case reports and case series and results of anonymous surveys of patients using cannabis outside of medical settings, with the original evidence classifications marked for those papers that followed research protocols. Despite overlap in some patients, dyskinesias will be treated separately from dystonia and chorea; benefit was not established beyond individual patients for these conditions. Tics, usually due to Tourettes, did respond to cannabis preparations. Side effects reported in the trials will be reviewed but those due to recreational use, including the dystonia that can be secondary to synthetic marijuana preparations, are outside the scope of this paper.

Entities:  

Keywords:  Cannabidiol; Cannabis; Chorea; Dyskinesias; Dystonia; Marijuana; THC; Tics

Mesh:

Substances:

Year:  2015        PMID: 26271953      PMCID: PMC4604174          DOI: 10.1007/s13311-015-0376-4

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  30 in total

Review 1.  Endocannabinoids in basal ganglia circuits: implications for Parkinson disease.

Authors:  Eduardo Benarroch
Journal:  Neurology       Date:  2007-07-17       Impact factor: 9.910

2.  Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial.

Authors:  Marcos Hortes N Chagas; Antonio W Zuardi; Vitor Tumas; Márcio Alexandre Pena-Pereira; Emmanuelle T Sobreira; Mateus M Bergamaschi; Antonio Carlos dos Santos; Antonio Lucio Teixeira; Jaime E C Hallak; José Alexandre S Crippa
Journal:  J Psychopharmacol       Date:  2014-09-18       Impact factor: 4.153

Review 3.  Medical marijuana in neurology.

Authors:  Selim R Benbadis; Juan Sanchez-Ramos; Ali Bozorg; Melissa Giarratano; Kavita Kalidas; Lara Katzin; Derrick Robertson; Tuan Vu; Amanda Smith; Theresa Zesiewicz
Journal:  Expert Rev Neurother       Date:  2014-12       Impact factor: 4.618

4.  Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta 9-THC): no influence on neuropsychological performance.

Authors:  Kirsten R Müller-Vahl; Heidrun Prevedel; Karen Theloe; Hans Kolbe; Hinderk M Emrich; Udo Schneider
Journal:  Neuropsychopharmacology       Date:  2003-02       Impact factor: 7.853

5.  Open label evaluation of cannabidiol in dystonic movement disorders.

Authors:  P Consroe; R Sandyk; S R Snider
Journal:  Int J Neurosci       Date:  1986-11       Impact factor: 2.292

6.  Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study.

Authors:  C B Carroll; P G Bain; L Teare; X Liu; C Joint; C Wroath; S G Parkin; P Fox; D Wright; J Hobart; J P Zajicek
Journal:  Neurology       Date:  2004-10-12       Impact factor: 9.910

7.  Current status of cannabis treatment of multiple sclerosis with an illustrative case presentation of a patient with MS, complex vocal tics, paroxysmal dystonia, and marijuana dependence treated with dronabinol.

Authors:  Stephen I Deutsch; Richard B Rosse; Julie M Connor; Jessica A Burket; Mary E Murphy; Fiona J Fox
Journal:  CNS Spectr       Date:  2008-05       Impact factor: 3.790

Review 8.  The endocannabinoid system as a target for the treatment of motor dysfunction.

Authors:  Javier Fernández-Ruiz
Journal:  Br J Pharmacol       Date:  2009-02-13       Impact factor: 8.739

Review 9.  Cannabinoids for Tourette's Syndrome.

Authors:  Adrienne Curtis; Carl E Clarke; Hugh E Rickards
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07

10.  Self-reported efficacy of cannabis and other complementary medicine modalities by Parkinson's disease patients in colorado.

Authors:  Taylor Andrew Finseth; Jessica Louise Hedeman; Robert Preston Brown; Kristina I Johnson; Matthew Sean Binder; Benzi M Kluger
Journal:  Evid Based Complement Alternat Med       Date:  2015-03-02       Impact factor: 2.629

View more
  9 in total

Review 1.  The neurobiological basis for novel experimental therapeutics in dystonia.

Authors:  Anthony M Downs; Kaitlyn M Roman; Simone A Campbell; Antonio Pisani; Ellen J Hess; Paola Bonsi
Journal:  Neurobiol Dis       Date:  2019-07-04       Impact factor: 5.996

2.  Natural Cannabinoids as Templates for Sleep Disturbances Treatments.

Authors:  Eric Murillo-Rodríguez; Sérgio Machado; Claudio Imperatori; Tetsuya Yamamoto; Henning Budde
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 3.  Randomized controlled trials on the use of cannabis-based medicines in movement disorders: a systematic review.

Authors:  P Oikonomou; W H Jost
Journal:  J Neural Transm (Vienna)       Date:  2022-07-20       Impact factor: 3.850

4.  Collagen VI Regulates Motor Circuit Plasticity and Motor Performance by Cannabinoid Modulation.

Authors:  Daniel D Lam; Rhîannan H Williams; Ernesto Lujan; Koji Tanabe; Georg Huber; Nay Lui Saw; Juliane Merl-Pham; Aaro V Salminen; David Lohse; Sally Spendiff; Melanie J Plastini; Michael Zech; Hanns Lochmüller; Arie Geerlof; Stefanie M Hauck; Mehrdad Shamloo; Marius Wernig; Juliane Winkelmann
Journal:  J Neurosci       Date:  2021-12-27       Impact factor: 6.709

Review 5.  Medical treatment of dystonia.

Authors:  Pichet Termsarasab; Thananan Thammongkolchai; Steven J Frucht
Journal:  J Clin Mov Disord       Date:  2016-12-19

6.  Benefits, Safety, and Adjunct Modality Prevalences of Long-Term Botulinum Toxin Injections for Cervical Dystonia and Myofascial Neck Pain: A Retrospective Cohort Study.

Authors:  Dion Diep; Jasmine Ko; John Lan; Kinga T Koprowicz; Gordon Ko
Journal:  J Pain Res       Date:  2020-06-03       Impact factor: 3.133

Review 7.  European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part III: pharmacological treatment.

Authors:  Veit Roessner; Heike Eichele; Jeremy S Stern; Liselotte Skov; Renata Rizzo; Nanette Mol Debes; Péter Nagy; Andrea E Cavanna; Cristiano Termine; Christos Ganos; Alexander Münchau; Natalia Szejko; Danielle Cath; Kirsten R Müller-Vahl; Cara Verdellen; Andreas Hartmann; Aribert Rothenberger; Pieter J Hoekstra; Kerstin J Plessen
Journal:  Eur Child Adolesc Psychiatry       Date:  2021-11-10       Impact factor: 4.785

Review 8.  Cannabinoids in Parkinson's Disease.

Authors:  Mario Stampanoni Bassi; Andrea Sancesario; Roberta Morace; Diego Centonze; Ennio Iezzi
Journal:  Cannabis Cannabinoid Res       Date:  2017-02-01

Review 9.  Distinctive Evidence Involved in the Role of Endocannabinoid Signalling in Parkinson's Disease: A Perspective on Associated Therapeutic Interventions.

Authors:  Tapan Behl; Gagandeep Kaur; Simona Bungau; Rishabh Jhanji; Arun Kumar; Vineet Mehta; Gokhan Zengin; Roxana Brata; Syed Shams Ul Hassan; Ovidiu Fratila
Journal:  Int J Mol Sci       Date:  2020-08-28       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.